Drug Trial Radar · NCT07831863
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Mar 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .
Conditions
- Lung Squamous Cell Carcinoma
Interventions
7MW3711Drug
Participants will receive intravenous (IV) infusion of 7MW3711 as per protocol
DocetaxelDrug
Participants will receive intravenous (IV) infusion of Docetaxel as per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Up to 34 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.